

ADDITIONAL SECONDARY OUTCOMES

| Adverse Events | Overall Population (N = 637) | | | | PS-matched Population (N = 492) | | | |
|---------------------------------------|------------------------------|-------------------|---------------------------|---------|---------------------------------|-------------------|-------------------|---------|
| | Clopidogrel (n = 266), % | DAPT (n = 371), % | aHR [†] (95% CI) | P value | Clopidogrel (n = 246), % | DAPT (n = 246), % | HR (95% CI) | P value |
| Individual components of MACCE | | | | | | | | |
| All-cause death | 3 | 1.6 | 0.47 (0.15-1.49) | 0.202 | 2.8 | 2 | 1.21 (0.54-2.75) | 0.714 |
| All-cause death or non-fatal MI | 3.8 | 3.2 | 0.81 (0.33-1.97) | 0.645 | 3.7 | 4.1 | 0.81 (0.26-2.54) | 0.631 |
| Cardiovascular death | 0.4 | 0.5 | | 0.599 | 0.4 | 0.8 | 1.25 (0.51-3.07) | 0.498 |
| Non-fatal MI | 0.8 | 1.6 | | 0.361 | 0.8 | 0.8 | | 0.919 |
| Probable/definite stent thrombosis | 0.4 | 0.3 | | 0.673 | 0.4 | 0 | | 0.61 |
| Stroke | 0.8 | 0.5 | | 0.86 | 0.8 | 0.8 | | 0.938 |
| Revascularization | | | | | | | | |
| TVR | 4.5 | 5.7 | 1.14 (0.55-2.38) | 0.727 | 4.5 | 4.9 | 1.10 (0.49-2.49) | 0.82 |
| TLR | 1.1 | 4 | 2.91 (0.81-10.52) | 0.092 | 0.8 | 3.3 | 4.05 (0.86-19.07) | 0.077 |

[†]Adjusted for age, sex, acute coronary syndrome during index admission, hypertension, diabetes, current smoker, chronic kidney disease, dyslipidemia, previous PCI, left main or left anterior descending artery as treated vessel, multi-vessel PCI, complex PCI, total stent numbers, and total stent length

ABBREVIATIONS:

aHR, adjusted HR; BARC, Bleeding Academic Research Consortium; CI, confidence interval; DAPT, dual anti-platelet therapy; HR, hazard ratio; MACCE, major adverse cardiac and cerebrovascular event; MI, myocardial infarction; PCI, percutaneous coronary intervention; TVR, target vessel revascularization; TLR, target lesion revascularization.